Tishchenko D G
This paper represents the results of pharmacoeconomic study of the drug pomalidomide use in treatment of patients with relapsed or refractory multiple myeloma (MM) with more than 50% reduction in M protein, who have received at least two lines of therapy comprising lenalidomide and bortezomib. Lenalidomide and bortezomib were used as comparative treatment options in the study. The pharmacoeconomic study was carried out using the methods for analysis of efficiency, cost, cost-effectiveness, sensitivity and impact on the budget under frame of the medicinal assistance program for people suffering from hemophilia, cystic fibrosis, pituitary dwarfism, Gaucher’s disease, formation of malignant lymphoid haematogenic and related tissues, multiple sclerosis, as well as organ and/or tissue transplants (hereinafter referred to as the Seven Nosologies (VZN) Program). The time horizon of the «impact on the budget» analysis for the “Seven Nosologies” program was consisted of 4 years (2015–2018). The pharmacoeconomic analysis showed that pomalidomide can be recommended for inclusion in the “Seven Nosologies” federal program within the existing budget. From the perspective of the cost-effectiveness analysis, pomalidomide is the dominant option, since the use of pomalidomide in the MM treatment has a significant advantage over lenalidomide and bortezomib therapy in terms of «cost of the average time to disease progression» and «value of survival time». In other words, pomalidomide therapy has the lowest cost of achieved efficiency unit. Analysis of the impact on the budget in case of pomalidomide (Imnovid) inclusion into the pattern of government procurement as part of the “Seven Nosologies” program for the target period (2016–2018) showed that pomalidomide inclusion will not lead to increase the program budget.
In this article the economic burden of multiple sclerosis in the Republic of Belarus is presented. Analysis is performed using calculation direct and indirect costs.
This document represents the results of validation of pharmacoeconomic model of introduction of medicinal product Ibrutinib into chronic lymphatic leukemia therapy practice within the programme of drug provision for patients with hemophilia, cystic fibrosis, pituitary dwarfism, Gaucher disease, malignant neoplasms of lymphoid, haematopoietic and related tissues, multiple sclerosis, as well as patients after transplantation of organs and/or tissues (hereafter referred to as ‘7 cost-intensive nosologies (7 CIN) programme’). Budget impact analysis demonstrated the possibility to provide all patients requiring Ibrutinib therapy without budget increase using only a part of savings within the programme during a period of 2016 – 2018.
Analysis of costs of using lanreotide in patients with GEP-NETs grade 1 or 2 originating from the pancreas(with tumor proliferation index of [Ki-67] <10%) was carried out in this study. Targeted drugs with indications for treatment of pancreatic NETs in the Russian Federation were used for comparison: sunitinib and everolimus. Pharmacoeconomic study was carried out using methods of «cost-effectiveness» analysis including a sensitivity analysis. The study considered the direct costs which included the costs of treatment and the methods of diagnosis according guidelines of RUSSCO (MRI, biopsy and biochemistry blood analysis). As a result, it was found that the average cost of main pharmacotherapy per patient annually using lanreotide is lower than the average cost of treatment using sunitinib or everolimus by 55.2% and 51.9% (845 000 roubles, 1,886,991 roubles and 1758 443 roubles), respectively. This pharmacoeconomic analysis showed that the average total cost of the main drug treatment and medical care services in the treatment of pancreatic NETs using lanreotide is 886,036 roubles. That is lower than the total cost of treatment using sunitinib (1,928,027 roubles) or everolimus ( 1,799,479 roubles) by 54.0% and 50.8%, respectively. When analyzing the ‘cost effectiveness’, progression-free survival (PFS) was chosen as an efficiency criterion. Considering the results of «cost - effectiveness» analysis, the use of lanreotide for the treatment of pancreatic NETs has a significant advantage over therapy using sunitinib or everolimus in terms of median progression-free survival (PFS), CER of lanreotide is lower than CERof sunitinib and CER of everolimus (73 836 rub/month, 160 660 rub/month and 149 957 rub/month respectively) i.e., lanreotide is the option in treatment. This study has limitations due to study design (lareotide open label study) and difference in population between lanreotide study and sunitinib and everolimus studies.
Pharmacoeconomic analysis of long-term effects of more widespread use of in vitro fertilization (IVF) in infertility treatment at the regional and federal level from the standpoint of society in the Russian Federation was carried out in this research. The research was performed by means of forecasting of future monetary flows produced by a human born with the aid of in vitro fertilization throughout life. The methods of cost analysis, discounted monetary flows, age shifting and model building were used in the research. The result is that net present value (NPV) of tax payments produced within anticipated life period by the human born with of IVF in the Russian Federation was equal to 822,258 rubles. Return on investments (ROI) was 27%. Net present value (NPV) of GDP produced within the state per one human born with the aid of IVF in the Russian Federation was equal to 34.9 million rubles. Return on investments (ROI) was 985%. Additional carrying out of 24,450 IVF cycles on the basis of OMI CMI (Obligatory Medical Insurance) (the level of 2013) results in increase of total growth of population of the Russian Federation by 22.5%, annual additional carrying out of IVF procedure in the quantity carried out in 2013 will allow to produce additional population growth by 2075 estimated at 319 thousand people in productive age, and 222 thousand people aged up to 20 years.
In this article the economic burden of multiple sclerosis in the Republic of Belarus is presented. Analysis is performed using calculation direct and indirect costs.
This document represents the results of validation of pharmacoeconomic model of introduction of medicinal product Ibrutinib into chronic lymphatic leukemia therapy practice within the programme of drug provision for patients with hemophilia, cystic fibrosis, pituitary dwarfism, Gaucher disease, malignant neoplasms of lymphoid, haematopoietic and related tissues, multiple sclerosis, as well as patients after transplantation of organs and/or tissues (hereafter referred to as ‘7 cost-intensive nosologies (7 CIN) programme’). Budget impact analysis demonstrated the possibility to provide all patients requiring Ibrutinib therapy without budget increase using only a part of savings within the programme during a period of 2016 – 2018.
This paper represents the results of pharmacoeconomic study of the drug pomalidomide use in treatment of patients with relapsed or refractory multiple myeloma (MM) with more than 50% reduction in M protein, who have received at least two lines of therapy comprising lenalidomide and bortezomib. Lenalidomide and bortezomib were used as comparative treatment options in the study. The pharmacoeconomic study was carried out using the methods for analysis of efficiency, cost, cost-effectiveness, sensitivity and impact on the budget under frame of the medicinal assistance program for people suffering from hemophilia, cystic fibrosis, pituitary dwarfism, Gaucher’s disease, formation of malignant lymphoid haematogenic and related tissues, multiple sclerosis, as well as organ and/or tissue transplants (hereinafter referred to as the Seven Nosologies (VZN) Program). The time horizon of the «impact on the budget» analysis for the “Seven Nosologies” program was consisted of 4 years (2015–2018). The pharmacoeconomic analysis showed that pomalidomide can be recommended for inclusion in the “Seven Nosologies” federal program within the existing budget. From the perspective of the cost-effectiveness analysis, pomalidomide is the dominant option, since the use of pomalidomide in the MM treatment has a significant advantage over lenalidomide and bortezomib therapy in terms of «cost of the average time to disease progression» and «value of survival time». In other words, pomalidomide therapy has the lowest cost of achieved efficiency unit. Analysis of the impact on the budget in case of pomalidomide (Imnovid) inclusion into the pattern of government procurement as part of the “Seven Nosologies” program for the target period (2016–2018) showed that pomalidomide inclusion will not lead to increase the program budget.
Analysis of costs of using lanreotide in patients with GEP-NETs grade 1 or 2 originating from the pancreas(with tumor proliferation index of [Ki-67] <10%) was carried out in this study. Targeted drugs with indications for treatment of pancreatic NETs in the Russian Federation were used for comparison: sunitinib and everolimus. Pharmacoeconomic study was carried out using methods of «cost-effectiveness» analysis including a sensitivity analysis. The study considered the direct costs which included the costs of treatment and the methods of diagnosis according guidelines of RUSSCO (MRI, biopsy and biochemistry blood analysis). As a result, it was found that the average cost of main pharmacotherapy per patient annually using lanreotide is lower than the average cost of treatment using sunitinib or everolimus by 55.2% and 51.9% (845 000 roubles, 1,886,991 roubles and 1758 443 roubles), respectively. This pharmacoeconomic analysis showed that the average total cost of the main drug treatment and medical care services in the treatment of pancreatic NETs using lanreotide is 886,036 roubles. That is lower than the total cost of treatment using sunitinib (1,928,027 roubles) or everolimus ( 1,799,479 roubles) by 54.0% and 50.8%, respectively. When analyzing the ‘cost effectiveness’, progression-free survival (PFS) was chosen as an efficiency criterion. Considering the results of «cost - effectiveness» analysis, the use of lanreotide for the treatment of pancreatic NETs has a significant advantage over therapy using sunitinib or everolimus in terms of median progression-free survival (PFS), CER of lanreotide is lower than CERof sunitinib and CER of everolimus (73 836 rub/month, 160 660 rub/month and 149 957 rub/month respectively) i.e., lanreotide is the option in treatment. This study has limitations due to study design (lareotide open label study) and difference in population between lanreotide study and sunitinib and everolimus studies.
Pharmacoeconomic analysis of long-term effects of more widespread use of in vitro fertilization (IVF) in infertility treatment at the regional and federal level from the standpoint of society in the Russian Federation was carried out in this research. The research was performed by means of forecasting of future monetary flows produced by a human born with the aid of in vitro fertilization throughout life. The methods of cost analysis, discounted monetary flows, age shifting and model building were used in the research. The result is that net present value (NPV) of tax payments produced within anticipated life period by the human born with of IVF in the Russian Federation was equal to 822,258 rubles. Return on investments (ROI) was 27%. Net present value (NPV) of GDP produced within the state per one human born with the aid of IVF in the Russian Federation was equal to 34.9 million rubles. Return on investments (ROI) was 985%. Additional carrying out of 24,450 IVF cycles on the basis of OMI CMI (Obligatory Medical Insurance) (the level of 2013) results in increase of total growth of population of the Russian Federation by 22.5%, annual additional carrying out of IVF procedure in the quantity carried out in 2013 will allow to produce additional population growth by 2075 estimated at 319 thousand people in productive age, and 222 thousand people aged up to 20 years.
